AU2009300607C1 - 7-piperidinoalkyl-3,4-dihydroquinolone derivative - Google Patents

7-piperidinoalkyl-3,4-dihydroquinolone derivative Download PDF

Info

Publication number: AU2009300607C1
Authority: AU; Australia
Prior art keywords: group; oxo; methyl; piperidin; tetrahydroquinolin
Prior art date: 2008-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2009300607A

Other languages

English (en)

Other versions

AU2009300607A1 (en

AU2009300607B2 (en

Inventor

Kosuke Kanuma

Madoka Kawamura

Naoki Miyakoshi

Tsuyoshi Shibata

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Taisho Pharmaceutical Co Ltd

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-02

Filing date

2009-09-30

Publication date

2014-08-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009300607(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-30 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2010-04-08 Publication of AU2009300607A1 publication Critical patent/AU2009300607A1/en

2014-02-27 Application granted granted Critical

2014-02-27 Publication of AU2009300607B2 publication Critical patent/AU2009300607B2/en

2014-08-07 Publication of AU2009300607C1 publication Critical patent/AU2009300607C1/en

Status Ceased legal-status Critical Current

2029-09-30 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AU2009300607A 2008-10-02 2009-09-30 7-piperidinoalkyl-3,4-dihydroquinolone derivative Ceased AU2009300607C1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2008-257072		2008-10-02
JP2008257072		2008-10-02
PCT/JP2009/067441 WO2010038901A1 (en)	2008-10-02	2009-09-30	7-piperidinoalkyl-3,4-dihydroquinolone derivative

Publications (3)

Publication Number	Publication Date
AU2009300607A1 AU2009300607A1 (en)	2010-04-08
AU2009300607B2 AU2009300607B2 (en)	2014-02-27
AU2009300607C1 true AU2009300607C1 (en)	2014-08-07

Family

ID=42073652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2009300607A Ceased AU2009300607C1 (en)	2008-10-02	2009-09-30	7-piperidinoalkyl-3,4-dihydroquinolone derivative

Country Status (28)

Country	Link
US (1)	US8461182B2 (pl)
EP (1)	EP2344471B1 (pl)
JP (1)	JP5541279B2 (pl)
KR (1)	KR20110067026A (pl)
CN (1)	CN102239159B (pl)
AR (1)	AR073727A1 (pl)
AU (1)	AU2009300607C1 (pl)
BR (1)	BRPI0925343A2 (pl)
CA (1)	CA2739513A1 (pl)
CL (1)	CL2011000734A1 (pl)
CO (1)	CO6321164A2 (pl)
CY (1)	CY1114165T1 (pl)
DK (1)	DK2344471T3 (pl)
ES (1)	ES2424393T3 (pl)
HR (1)	HRP20130728T1 (pl)
IL (1)	IL212070A (pl)
MX (1)	MX2011003500A (pl)
MY (1)	MY154337A (pl)
NZ (1)	NZ592008A (pl)
PE (1)	PE20110410A1 (pl)
PL (1)	PL2344471T3 (pl)
PT (1)	PT2344471E (pl)
RS (1)	RS52964B (pl)
RU (1)	RU2498981C2 (pl)
SI (1)	SI2344471T1 (pl)
UA (1)	UA105187C2 (pl)
WO (1)	WO2010038901A1 (pl)
ZA (1)	ZA201102315B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011219467A (ja) *	2010-03-26	2011-11-04	Taisho Pharmaceutical Co Ltd	７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬
CA2816753A1 (en)	2010-11-08	2012-05-18	Lycera Corporation	N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
JP6242868B2 (ja)	2012-05-08	2017-12-06	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
KR20150007300A (ko)	2012-05-08	2015-01-20	머크 샤프 앤드 돔 코포레이션	Ror감마 활성의 억제를 위한 테트라히드로나프티리딘 및 관련 비시클릭 화합물 및 질환의 치료
ES2998534T3 (en)	2013-03-12	2025-02-20	Bio Pharm Solutions Co Ltd	Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
WO2015095788A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095795A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
AU2015222917A1 (en)	2014-02-27	2016-09-15	Lycera Corporation	Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015171558A2 (en)	2014-05-05	2015-11-12	Lycera Corporation	BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JP6728061B2 (ja)	2014-05-05	2020-07-22	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
WO2016130818A1 (en)	2015-02-11	2016-08-18	Merck Sharp & Dohme Corp.	SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10421751B2 (en)	2015-05-05	2019-09-24	Lycera Corporation	Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CN107980042B (zh)	2015-06-11	2021-10-08	莱斯拉公司	用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
WO2017075182A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Substituted indazole compounds as rorgammat inhibitors and uses thereof
WO2017075185A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
JP2018531957A (ja)	2015-10-27	2018-11-01	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用
BR112018016475A2 (pt) *	2016-02-12	2018-12-26	Astellas Pharma Inc	derivados de tetrahidroisoquinolina

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050209274A1 (en) *	2004-02-26	2005-09-22	Lynch John K	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU222745B1 (hu) *	1995-09-15	2003-09-29	Sanofi-Synthelabo	Kinolin-2(1H)-on-származékok mint szerotonin antagonisták, elżállításuk és alkalmazásuk
WO2003028641A2 (en) *	2001-10-01	2003-04-10	Taisho Pharmaceutical Co., Ltd.	Mch receptor antagonists
IL161478A0 (en) *	2001-10-25	2004-09-27	Takeda Chemical Industries Ltd	Quinoline compound
CN100475793C (zh) *	2003-03-31	2009-04-08	大正制药株式会社	喹唑啉衍生物及其制备药物的用途
US20050197350A1 (en) *	2003-03-31	2005-09-08	Taisho Pharmaceutical Co., Ltd.	Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
NZ549673A (en) *	2004-03-30	2010-03-26	Taisho Pharmaceutical Co Ltd	Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006035967A1 (en) *	2004-09-30	2006-04-06	Taisho Pharmaceutical Co., Ltd.	Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
RU2009117182A (ru)	2006-10-06	2010-11-20	Тайсо Фармасьютикал Ко., Лтд. (Jp)	Производное 1-нафтилалкилпиперидина

2009
- 2009-09-30 WO PCT/JP2009/067441 patent/WO2010038901A1/en active Application Filing
- 2009-09-30 ES ES09817928T patent/ES2424393T3/es active Active
- 2009-09-30 UA UAA201105428A patent/UA105187C2/uk unknown
- 2009-09-30 BR BRPI0925343-2A patent/BRPI0925343A2/pt not_active IP Right Cessation
- 2009-09-30 KR KR1020117007343A patent/KR20110067026A/ko not_active Ceased
- 2009-09-30 DK DK09817928.6T patent/DK2344471T3/da active
- 2009-09-30 MY MYPI2011001430A patent/MY154337A/en unknown
- 2009-09-30 PE PE2011000810A patent/PE20110410A1/es not_active Application Discontinuation
- 2009-09-30 CA CA2739513A patent/CA2739513A1/en not_active Abandoned
- 2009-09-30 US US13/122,281 patent/US8461182B2/en not_active Expired - Fee Related
- 2009-09-30 RS RS20130370A patent/RS52964B/en unknown
- 2009-09-30 EP EP09817928.6A patent/EP2344471B1/en active Active
- 2009-09-30 RU RU2011117161/04A patent/RU2498981C2/ru not_active IP Right Cessation
- 2009-09-30 PL PL09817928T patent/PL2344471T3/pl unknown
- 2009-09-30 AU AU2009300607A patent/AU2009300607C1/en not_active Ceased
- 2009-09-30 NZ NZ592008A patent/NZ592008A/en not_active IP Right Cessation
- 2009-09-30 JP JP2011513768A patent/JP5541279B2/ja not_active Expired - Fee Related
- 2009-09-30 PT PT98179286T patent/PT2344471E/pt unknown
- 2009-09-30 SI SI200930738T patent/SI2344471T1/sl unknown
- 2009-09-30 MX MX2011003500A patent/MX2011003500A/es active IP Right Grant
- 2009-09-30 CN CN200980149091.2A patent/CN102239159B/zh not_active Expired - Fee Related
- 2009-10-01 AR ARP090103798A patent/AR073727A1/es unknown
2011
- 2011-03-29 ZA ZA2011/02315A patent/ZA201102315B/en unknown
- 2011-03-30 CO CO11038711A patent/CO6321164A2/es active IP Right Grant
- 2011-03-31 IL IL212070A patent/IL212070A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000734A patent/CL2011000734A1/es unknown
2013
- 2013-07-25 CY CY20131100633T patent/CY1114165T1/el unknown
- 2013-08-01 HR HRP20130728AT patent/HRP20130728T1/hr unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050209274A1 (en) *	2004-02-26	2005-09-22	Lynch John K	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

Also Published As

Publication number	Publication date
PT2344471E (pt)	2013-08-01
MX2011003500A (es)	2011-05-02
HK1159622A1 (en)	2012-08-03
NZ592008A (en)	2011-12-22
CA2739513A1 (en)	2010-04-08
BRPI0925343A2 (pt)	2015-07-28
CN102239159A (zh)	2011-11-09
UA105187C2 (uk)	2014-04-25
AU2009300607A1 (en)	2010-04-08
IL212070A (en)	2014-07-31
SI2344471T1 (sl)	2013-11-29
EP2344471B1 (en)	2013-07-24
AR073727A1 (es)	2010-11-24
RU2498981C2 (ru)	2013-11-20
US20110178304A1 (en)	2011-07-21
PL2344471T3 (pl)	2013-12-31
PE20110410A1 (es)	2011-07-02
MY154337A (en)	2015-05-29
RS52964B (en)	2014-02-28
CO6321164A2 (es)	2011-09-20
HRP20130728T1 (en)	2013-10-11
DK2344471T3 (da)	2013-10-07
CN102239159B (zh)	2014-06-25
RU2011117161A (ru)	2012-11-10
WO2010038901A1 (en)	2010-04-08
IL212070A0 (en)	2011-06-30
EP2344471A4 (en)	2012-05-30
ES2424393T3 (es)	2013-10-01
EP2344471A1 (en)	2011-07-20
CY1114165T1 (el)	2016-08-31
US8461182B2 (en)	2013-06-11
JP5541279B2 (ja)	2014-07-09
AU2009300607B2 (en)	2014-02-27
JP2012504549A (ja)	2012-02-23
KR20110067026A (ko)	2011-06-20
ZA201102315B (en)	2012-06-27
CL2011000734A1 (es)	2011-09-23

Publication	Publication Date	Title
AU2009300607C1 (en)	2014-08-07	7-piperidinoalkyl-3,4-dihydroquinolone derivative
JP6211509B2 (ja)	2017-10-11	複素環化合物およびその用途
JP6571077B2 (ja)	2019-09-04	含窒素複素環化合物
AU2013280779B2 (en)	2015-09-10	Dimethyl-benzoic acid compounds
CA2748251A1 (en)	2010-07-01	Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor
EP2565191A1 (en)	2013-03-06	4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
MXPA00004940A (es)	2002-10-17	Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central.
KR20090034899A (ko)	2009-04-08	도파민 ｄ3 수용체 리간드로서의 신규 카보닐화된 (아자)사이클로헥산
KR20040103973A (ko)	2004-12-09	Ｎ-[페닐(피페리딘-2-일)메틸]벤즈아미드의 유도체, 그의제조 방법 및 치료법에서의 그의 용도
US7947714B2 (en)	2011-05-24	Piperidine glycine transporter inhibitors
SK6112003A3 (en)	2004-04-06	Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for the treatment of nervous system disorders
AU2009207750A1 (en)	2009-07-30	Sulfonamides as orexin antagonists
JP2002530378A (ja)	2002-09-17	Ｎｋ−２およびｎｋ−３受容体リガンドとしてのキノリン誘導体
WO2009099177A1 (ja)	2009-08-13	アミノイミダゾール誘導体
JP2009179562A (ja)	2009-08-13	グリシントランスポーター阻害剤
JP2011219467A (ja)	2011-11-04	７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬
US20100081825A1 (en)	2010-04-01	1-naphthyl alkylpiperidine derivative
WO2010050191A1 (ja)	2010-05-06	１，２－ジアゼチジン－３－オン誘導体及びこれを含有する医薬
HK1159622B (en)	2015-06-26	7-piperidinoalkyl-3,4-dihydroquinolone derivative
JP2009185010A (ja)	2009-08-20	グリシントランスポーター阻害剤を含有する医薬
JPH08208595A (ja)	1996-08-13	スルホンアミド化合物、その製造法および剤
HK1136552A (en)	2010-07-02	1-naphthyl alkylpiperidine derivative

Legal Events

Date	Code	Title	Description
2014-05-08	DA2	Applications for amendment section 104	Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 APR 2014 .
2014-08-07	DA3	Amendments made section 104	Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 APR 2014
2014-08-14	FGA	Letters patent sealed or granted (standard patent)
2017-04-27	MK14	Patent ceased section 143(a) (annual fees not paid) or expired